Factor XI as a Therapeutic Target

David Gailani, Andras Gruber

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Factor XIa is a plasma serine protease that contributes to thrombin generation primarily through proteolytic activation of factor IX. Traditionally considered part of the intrinsic pathway of coagulation, several lines of evidence now suggest that factor XIa serves as an interface between the vitamin-K–dependent thrombin generation mechanism and the proinflammatory kallikrein–kinin system, allowing the 2 systems to influence each other. Work with animal models and results from epidemiological surveys of human populations support a role for factor XIa in thromboembolic disease. These data and the clinical observation that deficiency of factor XI, the zymogen of factor XIa, produces a relatively mild bleeding disorder suggest that drugs targeting factor XI or XIa could produce an antithrombotic effect while leaving hemostasis largely intact. Results of a recent trial comparing antisense-induced factor XI reduction to standard-dose low molecular–weight heparin as prophylaxis for venous thrombosis during knee replacement are encouraging in these regards. Here, we discuss recent findings on the biochemistry, physiology, and pathology of factor XI because they relate to thromboembolic disease.

Original languageEnglish (US)
JournalArteriosclerosis, Thrombosis, and Vascular Biology
DOIs
StateAccepted/In press - May 12 2016

Fingerprint

Factor XIa
Factor XI
Thrombin
Factor XI Deficiency
Therapeutics
Enzyme Precursors
Factor IX
Serine Proteases
Drug Delivery Systems
Hemostasis
Vitamins
Venous Thrombosis
Biochemistry
Heparin
Knee
Animal Models
Pathology
Hemorrhage
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Factor XI as a Therapeutic Target. / Gailani, David; Gruber, Andras.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, 12.05.2016.

Research output: Contribution to journalArticle

@article{468cd4159b5640d6873212244f5f585b,
title = "Factor XI as a Therapeutic Target",
abstract = "Factor XIa is a plasma serine protease that contributes to thrombin generation primarily through proteolytic activation of factor IX. Traditionally considered part of the intrinsic pathway of coagulation, several lines of evidence now suggest that factor XIa serves as an interface between the vitamin-K–dependent thrombin generation mechanism and the proinflammatory kallikrein–kinin system, allowing the 2 systems to influence each other. Work with animal models and results from epidemiological surveys of human populations support a role for factor XIa in thromboembolic disease. These data and the clinical observation that deficiency of factor XI, the zymogen of factor XIa, produces a relatively mild bleeding disorder suggest that drugs targeting factor XI or XIa could produce an antithrombotic effect while leaving hemostasis largely intact. Results of a recent trial comparing antisense-induced factor XI reduction to standard-dose low molecular–weight heparin as prophylaxis for venous thrombosis during knee replacement are encouraging in these regards. Here, we discuss recent findings on the biochemistry, physiology, and pathology of factor XI because they relate to thromboembolic disease.",
author = "David Gailani and Andras Gruber",
year = "2016",
month = "5",
day = "12",
doi = "10.1161/ATVBAHA.116.306925",
language = "English (US)",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Factor XI as a Therapeutic Target

AU - Gailani, David

AU - Gruber, Andras

PY - 2016/5/12

Y1 - 2016/5/12

N2 - Factor XIa is a plasma serine protease that contributes to thrombin generation primarily through proteolytic activation of factor IX. Traditionally considered part of the intrinsic pathway of coagulation, several lines of evidence now suggest that factor XIa serves as an interface between the vitamin-K–dependent thrombin generation mechanism and the proinflammatory kallikrein–kinin system, allowing the 2 systems to influence each other. Work with animal models and results from epidemiological surveys of human populations support a role for factor XIa in thromboembolic disease. These data and the clinical observation that deficiency of factor XI, the zymogen of factor XIa, produces a relatively mild bleeding disorder suggest that drugs targeting factor XI or XIa could produce an antithrombotic effect while leaving hemostasis largely intact. Results of a recent trial comparing antisense-induced factor XI reduction to standard-dose low molecular–weight heparin as prophylaxis for venous thrombosis during knee replacement are encouraging in these regards. Here, we discuss recent findings on the biochemistry, physiology, and pathology of factor XI because they relate to thromboembolic disease.

AB - Factor XIa is a plasma serine protease that contributes to thrombin generation primarily through proteolytic activation of factor IX. Traditionally considered part of the intrinsic pathway of coagulation, several lines of evidence now suggest that factor XIa serves as an interface between the vitamin-K–dependent thrombin generation mechanism and the proinflammatory kallikrein–kinin system, allowing the 2 systems to influence each other. Work with animal models and results from epidemiological surveys of human populations support a role for factor XIa in thromboembolic disease. These data and the clinical observation that deficiency of factor XI, the zymogen of factor XIa, produces a relatively mild bleeding disorder suggest that drugs targeting factor XI or XIa could produce an antithrombotic effect while leaving hemostasis largely intact. Results of a recent trial comparing antisense-induced factor XI reduction to standard-dose low molecular–weight heparin as prophylaxis for venous thrombosis during knee replacement are encouraging in these regards. Here, we discuss recent findings on the biochemistry, physiology, and pathology of factor XI because they relate to thromboembolic disease.

UR - http://www.scopus.com/inward/record.url?scp=84966728651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966728651&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.116.306925

DO - 10.1161/ATVBAHA.116.306925

M3 - Article

C2 - 27174099

AN - SCOPUS:84966728651

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

ER -